Skip to content Skip to footer
Subscribe Now
NEWS

Novartis to Acquire Tourmaline Bio for ~$1.4B, Complementing its Cardiovascular Portfolio

Shots:Novartis has entered into an agreement to acquire Tourmaline Bio, incl. its asset pacibekitug, expanding its cardiovascular portfolioAs per the deal, Novartis, through its subsidiary, will acquire Tourmaline for $48/share, representing an aggregate of ~$1.4B, & will merge the subsidiary into Tourmaline upon completion, making it an indirect wholly owned unit of Novartis; closing…
September 9, 2025

Read more

NEWS

Argo Biopharma Inks a ~$5.3B Deal with Novartis for Multiple Cardiovascular Assets, Expanding their Existing Partnership

Shots:Argo has entered into an additional strategic collaboration with Novartis for multiple CV assetsNovartis has obtained an option to license ex-China rights to two discovery-stage molecules for sHTG & mixed dyslipidemia, plus first negotiation rights to BW-00112 (ANGPTL3), a P-II asset. Deal also incl. a reciprocal P&L-sharing license for a hepatic siRNA asset…
September 4, 2025

Read more

VIEWPOINTS_Nabil Abadir_2023
VIEWPOINTS

Nabil Abadir, CMO and Head of Global Medical Affairs at Amarin Corp Shares Insights from New Data Evaluating Vascepa/Vazkepa at ACC.23/WCC

Shots:Nabil spoke about the data evaluating Vascepa/Vazkepa and eicosapentaenoic acid in reducing cardiovascular events presented at the ACC.23/WCCHe also told our readers about the new analysis from the REDUCE-IT trial showing the effectiveness of VASCEPA/VAZKEPA in patients with recent acute coronary syndromeThe interview shows how Amarin is developing innovative therapies, increasing the…
July 18, 2023

Read more

VIEWPOINTS_Jason-Winnike_2023
VIEWPOINTS

Jason Winnike, Study Director at Metabolon Shares Insights from the Launch of its Oxysterol Targeted Panel

Shots:Jason shared his views on the launch of Metabolon, Inc.’s new Oxysterols Targeted Panel, highlighting its key features He told how the panel measures 12 oxysterols and related sterols of biological significance to identify biomarkers for the prediction and early detection of cardiovascular diseases, neurodegenerative diseases, and cancer The interview gives a profound understanding…
March 6, 2023

Read more

Viewpoints_Matt Killeen
VIEWPOINTS

Matt Killeen, CSO at Renovacor Shares Insights on Pipeline Expansion through its AAV Gene Therapy Program

Shots:Matt spoke about the new research program for multiple genetic segments of arrhythmogenic cardiomyopathyHe also highlighted Renovacor’s research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI)The interview shows Renovacor’s pipeline expansion to develop transformative therapies in genetically-driven cardiovascular diseasesSmriti: Please give readers a brief insight…
September 12, 2022

Read more

PharmaShots Interview Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results
VIEWPOINTS

PharmaShots Interview: Dr. R. Preston Mason, Consultant at Amarin, Corp. Shares Insights from its in vitro Study Results

Shots:Dr. Mason spoke about the key findings from their in vitro study demonstrating EPA + statins effects in reduced lipid oxidation, which were presented at the ACC 2022He also spoke about the study design of the REDUCE-IT trial and its importance in the approval of its candidate in metabolic and cardiovascular diseasesThe interview summarizes…
August 3, 2022

Read more